Sanofi - Aventis Groupe: Press Release: Pivotal data demonst

Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Investigational once-weekly efanesoctocog alfa prophylaxis met the

Related Keywords

Stockholm , Sweden , United States , Paris , France General , France , Russia , Willebrand , Nordrhein Westfalen , Germany , America , Eva Schaefer Jansen , Corentine Driancourt , Felix Lauscher , Anders Ullman , Kate Conway , Nathalie Pham , Sandrine Guendoul , Dietmar Berger , Sally Bain , Priya Nanduri , Hemophilia Joint Health , Linkedin , Global Head Of Development , International Society On Thrombosis , European Commission , Drug Administration , Sobi Investor Relations Team , Nasdaq , Youtube , Thrombosis Treatment Center , Euronext , Swedish Orphan Biovitrum , International Society , Chief Medical Officer , Breakthrough Therapy Designation , Fast Track , Orphan Drug , Biologics License Application , North Africa , Middle Eastern , North America , Middle East , Sobi Media , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Haema Qol Physical Health , Sanofi , Eventis , Roupe , Dress , Release , Pivotal , Data , Emonstrate , Dance , Weekly , Fanesoctocog , Alfa , Rovides , Superior , Bleed , Protection , Ompared , Rior , Factor , Prophylaxis ,